We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Introduces CoE in Clinical Metabolomics
Read MoreHide Full Article
Thermo Fisher Scientific Inc. (TMO - Free Report) , in collaboration with the University of California, Davis (UC Davis) West Coast Metabolomics Center, recently announced the launch of “The Center of Excellence (CoE) in Clinical Metabolomics.” The research collaboration is aimed to offer the metabolomics community with advanced, best practices and standard operating procedures to help in the rapid development of a large cohort studies and clinical research.
The recent collaboration is likely to boost Thermo Fisher’s Specialty Diagnostics segment.
More in the News
It is to be noted that metabolomics is an increasingly vital field where researchers recognize diagnostic biomarkers for disease, discover new drug targets, develop tools to predict drug response, and facilitate precision medicine overall. Development in this field can help ensure that patients get more targeted medicines and increase the probability that those therapies will achieve their anticipated outcomes.
Based on the UC Davis Sacramento campus, The CoE in Clinical Metabolomics will allow targeted and untargeted metabolic profiling for large-scale population-based cohorts across translational research and precision medicine.
Image Source: Zacks Investment Research
The Center will create standardized processes for the research community, including end-to-end metabolic profiling workflows, optimized liquid chromatography-mass spectrometry (LC-MS) methods, protocols for analytical controls to scrutinize instrument performance and training courses for metabolomics staff, scientists and core lab managers.
Significance of the Collaboration
The collaboration will boost the creation of advanced analytical approaches for both untargeted and targeted applications by offering the metabolomics community with highly developed methodologies for their vital work.
Thermo Fisher is providing its powerful Orbitrap technology as part of the collaboration. The Center will produce high-quality data using the newest generation of Orbitrap-based mass spectrometers in combination with the Thermo Scientific Vanquish Duo UHPLC system for increased throughput. The combination of these instruments will aid the progress of streamlined workflows for large-scale studies and translational research.
Industry Prospects
Per a report by MarketsandMarkets, the global metabolomics market size was valued at $1.9 billion in 2020 and is projected to reach $4.1 billion by 2025 at a CAGR of 13.4%. Rising R&D expenditure in the pharmaceutical & biopharmaceutical industry, availability of government and private funding for metabolomics research and ongoing innovations in metabolomics instruments are the factors driving the market.
Recent Developments
In July 2021, Thermo Fisher collaborated with Ortho Clinical Diagnostics to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analyzers.
In June 2021, Thermo Fisher launched the Ion AmpliSeq SARS-CoV-2 Insight Research Assay to advance SARS-CoV-2 surveillance designed to allow early identification of new and known variants from samples that have lower viral loads. This assay widens and enhances local, regional and national surveillance efforts to discover emerging SARS-CoV-2 variants through highly sensitive next-generation sequencing (NGS).
Price Performance
Shares of the company have gained 35.2% in a year’s time compared with the industry’s rise of 21.9%.
Zacks Rank and Key Picks
Currently, the company carries a Zacks Rank #3 (Hold).
Envista Holdings has an estimated long-term earnings growth rate of 26%.
BellRing Brands has an estimated long-term earnings growth rate of 22%.
Baxter International has a projected long-term earnings growth rate of 9%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Shutterstock
Thermo Fisher (TMO) Introduces CoE in Clinical Metabolomics
Thermo Fisher Scientific Inc. (TMO - Free Report) , in collaboration with the University of California, Davis (UC Davis) West Coast Metabolomics Center, recently announced the launch of “The Center of Excellence (CoE) in Clinical Metabolomics.” The research collaboration is aimed to offer the metabolomics community with advanced, best practices and standard operating procedures to help in the rapid development of a large cohort studies and clinical research.
The recent collaboration is likely to boost Thermo Fisher’s Specialty Diagnostics segment.
More in the News
It is to be noted that metabolomics is an increasingly vital field where researchers recognize diagnostic biomarkers for disease, discover new drug targets, develop tools to predict drug response, and facilitate precision medicine overall. Development in this field can help ensure that patients get more targeted medicines and increase the probability that those therapies will achieve their anticipated outcomes.
Based on the UC Davis Sacramento campus, The CoE in Clinical Metabolomics will allow targeted and untargeted metabolic profiling for large-scale population-based cohorts across translational research and precision medicine.
The Center will create standardized processes for the research community, including end-to-end metabolic profiling workflows, optimized liquid chromatography-mass spectrometry (LC-MS) methods, protocols for analytical controls to scrutinize instrument performance and training courses for metabolomics staff, scientists and core lab managers.
Significance of the Collaboration
The collaboration will boost the creation of advanced analytical approaches for both untargeted and targeted applications by offering the metabolomics community with highly developed methodologies for their vital work.
Thermo Fisher is providing its powerful Orbitrap technology as part of the collaboration. The Center will produce high-quality data using the newest generation of Orbitrap-based mass spectrometers in combination with the Thermo Scientific Vanquish Duo UHPLC system for increased throughput. The combination of these instruments will aid the progress of streamlined workflows for large-scale studies and translational research.
Industry Prospects
Per a report by MarketsandMarkets, the global metabolomics market size was valued at $1.9 billion in 2020 and is projected to reach $4.1 billion by 2025 at a CAGR of 13.4%. Rising R&D expenditure in the pharmaceutical & biopharmaceutical industry, availability of government and private funding for metabolomics research and ongoing innovations in metabolomics instruments are the factors driving the market.
Recent Developments
In July 2021, Thermo Fisher collaborated with Ortho Clinical Diagnostics to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analyzers.
In June 2021, Thermo Fisher launched the Ion AmpliSeq SARS-CoV-2 Insight Research Assay to advance SARS-CoV-2 surveillance designed to allow early identification of new and known variants from samples that have lower viral loads. This assay widens and enhances local, regional and national surveillance efforts to discover emerging SARS-CoV-2 variants through highly sensitive next-generation sequencing (NGS).
Price Performance
Shares of the company have gained 35.2% in a year’s time compared with the industry’s rise of 21.9%.
Zacks Rank and Key Picks
Currently, the company carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Envista Holdings Corporation (NVST - Free Report) , BellRing Brands, Inc. (BRBR - Free Report) and Baxter International Inc. (BAX - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
BellRing Brands has an estimated long-term earnings growth rate of 22%.
Baxter International has a projected long-term earnings growth rate of 9%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>